Back to search results

Oxytocin for Pain After Hysterectomy

This study is testing if intravenous (IV) oxytocin can help reduce pain and the need for pain medication after a minimally invasive hysterectomy (surgery to remove the uterus). Researchers will compare oxytocin to a placebo (a substance with no active medicine, in this case, 0.9% saline). You might be able to join if you are a woman between 18 and 65 years old, are generally healthy (ASA category 1-3), and are scheduled for a minimally invasive hysterectomy. The main goal is to see how much pain you experience 2-4 hours after surgery. The study aims to enroll 152 participants, but its current status is unclear.

Study design
This is a randomized, double-blinded, placebo-controlled study involving 152 women. Participants will be randomly assigned to receive either oxytocin or a placebo, and neither you nor your doctors will know which one you are receiving.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, post-operative pain, is measured between 2-4 hours after surgery completion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06483659

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Brigham and Women's Hospital
~152 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:OxytocinPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Post-operative pain
Measured over Between 2-4 hours after surgery completion (in the PACU)

Conditions

Postoperative Pain

Explore related trials

Post-Operative Pain

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

John J. Kowalczyk, MD
[email protected]
617-732-8220
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 18-65 years old
ASA category 1-3
Scheduled to undergo minimally invasive hysterectomy
No documented allergy to oxytocin

Exclusion

American Society of Anesthesiologists (ASA) group 4 or greater
Age \>65 years old
Additional surgical procedures including but not limited to minor laparotomy, omentectomy, cystectomy, vaginectomy, and/or ablation of endometriosis.
Active opioid prescription of the equivalent of oxycodone \>10 mg /day
Opioid use disorder, including patients in treatment receiving naltrexone or Suboxone (Buprenorphine-naloxone)
Allergies to any study medication: acetaminophen, celecoxib, ketorolac, fentanyl, hydromorphone, or oxycodone.
Epidural/Regional anesthesia for intra-operative or post-operative pain.
Inability to understand the questionnaires
Intra-operative and post-operative exclusion: Procedure converted to open or extension of primary surgery, Intra-operative EBL \>500 ml., Placement of epidural catheter or regional anesthesia at PACU for pain management, Hospitalization of the patient due to surgical or anesthetic complications

What this trial measures

  • Post-operative painBetween 2-4 hours after surgery completion (in the PACU)

    Assess the impact of a perioperative infusion of oxytocin on postoperative pain, the average patient pain scores measured as a mean Brief Pain Inventory in PACU after laparoscopic hysterectomy in treated and untreated groups will be compared